Glaucoma News and Research

Latest Glaucoma News and Research

Georgia Tech findings advance glaucoma research

Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent. New findings at Georgia Tech, published in January during Glaucoma Awareness Month, explore one of the many molecular origins of glaucoma and advance research dedicated to fighting the disease.

18 Jan 2012

New computational modeling methods book for ophthalmologists

Dr. Sumeet Dua, the Upchurch Endowed Professor of Computer Science and coordinator of information technology research at Louisiana Tech University, has co-edited a new book on computational modeling methods that can help ophthalmologists develop innovative computer systems to provide critical support and better care options for patients.

18 Jan 2012

IUPUI launches Institute for Mathematical Modeling and Computational Science

The School of Science at Indiana University-Purdue University Indianapolis has launched the Institute for Mathematical Modeling and Computational Science, an interdisciplinary endeavor dedicated to solving perplexing problems in such diverse fields as medicine, the environment, and computer science. iM2CS's parallel mission is to train a new generation to identify and solve the scientific issues with which they will be faced.

11 Jan 2012

Clearside Biomedical receives $4M venture capital investment

Technology developed by researchers at the Georgia Institute of Technology and Emory University for delivering drugs and other therapeutics to specific locations in the eye provides the foundation for a startup company that has received a $4 million venture capital investment.

6 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Study finds risk factors associated with exfoliation syndrome

When it comes to whether or not you will develop exfoliation syndrome (ES) -- an eye condition that is a leading cause of secondary open-angle glaucoma and increased risk of cataract as well as cataract surgery complications -- age, gender and where you live does matter.

2 Jan 2012

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Denali Concrete Management Inc. announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome.

21 Dec 2011

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Pfizer Inc. announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 - Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder.

6 Dec 2011

U.S. Marshals seize all Syntec's dietary supplements for false claims

U.S. Marshals, at the request of the FDA, today seized all dietary supplements by a Wisconsin maker for false claims made about their safety and effectiveness in treating a number of diseases.

2 Dec 2011

AHAF: Requests for ADR research grants increase by 33% this year

The American Health Assistance Foundation (AHAF), a nonprofit organization funding innovative research through its Alzheimer's Disease Research (ADR) program, today announced that the number of scientists seeking ADR research grants through its annual application process increased by 33% this year.

11 Nov 2011

ACADIA third quarter revenues decrease to $584,000

9 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

Laser therapy to turn brown eyes blue

A laser treatment developed by Stroma Medical's Dr. Gregg Homer takes only 20 seconds to perform but can turn brown eyes into blue ones permanently.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.

3 Nov 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Older adults with glaucoma at increased risk of falls

Older adults with glaucoma are at increased risk of falls resulting in injury, reports a study in the November issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

24 Oct 2011

Macular degeneration drug may cause increased IOP

Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye. It led to a retrospective study and findings that will be presented at the American Academy of Ophthalmology in Orlando.

24 Oct 2011

Carl Zeiss Meditec to showcase new clinical and productivity tools at AAO annual meeting

Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.

24 Oct 2011

Positive top line results from Shire's LDX phase III study on ADHD

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

22 Oct 2011

Glaucoma News and Research

Latest Glaucoma News and Research

Georgia Tech findings advance glaucoma research

New computational modeling methods book for ophthalmologists

IUPUI launches Institute for Mathematical Modeling and Computational Science

Clearside Biomedical receives $4M venture capital investment

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Study finds risk factors associated with exfoliation syndrome

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

U.S. Marshals seize all Syntec's dietary supplements for false claims

AHAF: Requests for ADR research grants increase by 33% this year

ACADIA third quarter revenues decrease to $584,000

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Laser therapy to turn brown eyes blue

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Older adults with glaucoma at increased risk of falls

Macular degeneration drug may cause increased IOP

Carl Zeiss Meditec to showcase new clinical and productivity tools at AAO annual meeting

Positive top line results from Shire's LDX phase III study on ADHD

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in